Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Authors
Keywords
-
Journal
Oncogenesis
Volume 7, Issue 2, Pages -
Publisher
Springer Nature
Online
2018-02-22
DOI
10.1038/s41389-018-0026-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies
- (2016) Giuseppa Pistritto et al. Aging-US
- A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma
- (2016) S. Thomas et al. ANNALS OF ONCOLOGY
- Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines
- (2016) Aleksandra Pettke et al. ANTI-CANCER DRUGS
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
- (2016) Daniel J Klionsky et al. Autophagy
- Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells
- (2016) Francesca Angeletti et al. Frontiers in Molecular Neuroscience
- Oncogenic Intra-p53 Family Member Interactions in Human Cancers
- (2016) Maria Ferraiuolo et al. Frontiers in Oncology
- A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†
- (2015) Q. S.-C. Chu et al. ANNALS OF ONCOLOGY
- Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
- (2015) Jianbin Zhang et al. Autophagy
- FOXO transcription factors in cancer development and therapy
- (2015) Alexandra Coomans de Brachène et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells
- (2015) Gemma Di Pompo et al. JOURNAL OF MEDICINAL CHEMISTRY
- HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components
- (2015) G. Lopez et al. MOLECULAR CANCER RESEARCH
- Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy
- (2015) S Fulda et al. ONCOGENE
- Sarcomas
- (2015) Josephine H. HaDuong et al. PEDIATRIC CLINICS OF NORTH AMERICA
- Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
- (2015) Claudia Blattmann et al. Radiation Oncology
- FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression
- (2015) H Guan et al. Oncogenesis
- HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
- (2015) Emily Koeneke et al. Cells
- The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway
- (2015) Michel Schmitt-Ney et al. PLoS One
- Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
- (2015) Valerie B. Sampson et al. PLoS One
- Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials
- (2014) A. Le Cesne et al. ANNALS OF ONCOLOGY
- Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
- (2014) S Bauer et al. BRITISH JOURNAL OF CANCER
- Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma
- (2014) Edwin Choy et al. CANCER
- Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas
- (2014) Roberta Zappasodi et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer
- (2014) Donatella Del Bufalo et al. Molecular Cancer
- Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line
- (2014) Enrico Capobianco et al. PLoS One
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- (2013) P A Cassier et al. BRITISH JOURNAL OF CANCER
- Sarcoma Chemotherapy
- (2013) B. E. Walczak et al. JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
- Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
- (2013) M V Stankov et al. LEUKEMIA
- The thiazole derivative CPTH6 impairs autophagy
- (2013) Y Ragazzoni et al. Cell Death & Disease
- Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines
- (2012) Venugopal Thayanithy et al. PLoS One
- Systemic therapy for advanced soft tissue sarcomas
- (2011) Richard F. Riedel CANCER
- Unknown
- (2011) Antonio Furlan et al. MOLECULAR MEDICINE
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor
- (2010) L Su et al. ONCOGENE
- Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
- (2009) G. Lopez et al. CLINICAL CANCER RESEARCH
- Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b
- (2009) K. Todoerti et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started